BioCentury | Feb 22, 2019
Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer immunotherapy pipeline. Merck will pay $5.85 per share in cash, or about $300 million. The price is...
BioCentury | Feb 21, 2019
Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer immunotherapy pipeline. Merck will pay $5.85 per share in cash, or about $300 million. The price is...
BioCentury | Oct 12, 2018
Clinical News

Immune Design deprioritizes synovial sarcoma compound CMB305

Immune Design Corp. (NASDAQ:IMDZ) discontinued the Phase III SYNOVATE trial of CMB305 monotherapy to treat synovial sarcoma after an early analysis of a Phase II trial in the indication showed that CMB305 in combination with...
BioCentury | May 4, 2018
Clinical News

Immune Design reports Phase I OS data for CMB305 in STS

In March, Immune Design Corp. (NASDAQ:IMDZ) reported data from 25 patients with cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-positive soft tissue sarcoma (STS) in an open-label, U.S. Phase I trial showing that CMB305 as monotherapy led to...
BioCentury | Oct 27, 2017
Financial News

Immune Design raises $80M follow-on

On Oct. 24, immunotherapy company Immune Design Corp. (NASDAQ:IMDZ) raised $80 million through the sale of 19.5 million shares at $4.10 in a follow-on underwritten by Leerink, Cowen and RBC Capital Markets. The price is...
BioCentury | Oct 25, 2017
Financial News

Immune Design raises $80M in follow-on

Immune Design Corp. (NASDAQ:IMDZ) raised $80 million late Tuesday through the sale of 19.5 million shares at $4.10 in a follow-on underwritten by Leerink, Cowen and RBC Capital Markets. The price is a 21% discount...
BioCentury | Sep 15, 2017
Clinical News

Immune Design reports Phase II STS data for CMB305

Immune Design Corp. (NASDAQ:IMDZ) reported interim data from a Phase II trial evaluating CMB305 (ID-CMB305) plus Tecentriq atezolizumab compared to Tecentriq alone to treat soft tissue sarcoma (STS). In a prespecified interim analysis of 36...
BioCentury | Sep 9, 2017
Clinical News

Immune Design reports Phase II STS data for CMB305

Immune Design Corp. (NASDAQ:IMDZ) reported interim data from a Phase II trial evaluating CMB305 plus Tecentriq atezolizumab compared to Tecentriq alone to treat soft tissue sarcoma. In a prespecified interim analysis of 36 evaluable patients,...
BioCentury | Feb 15, 2016
Clinical News

CMB305: Phase Ib data

Top-line data from an open-label, dose-escalation, U.S. Phase Ib trial in patients with locally advanced, relapsed or metastatic cancers expressing NY-ESO-1 showed that CMB305 was safe with no dose-limiting toxicities (DLTs) reported. Immune Design also...
BioCentury | Dec 7, 2015
Clinical News

Atezolizumab: Phase II started

Immune Design Corp. (NASDAQ:IMDZ, Seattle, Wash.) began an open-label, U.S. Phase II trial to compare CMB305 with atezolizumab vs. atezolizumab alone in up to 80 patients. Immune Design is developing CMB305, a combination of LV305...
Items per page:
1 - 10 of 18